The Motley Fool·2026-02-21 01:15Core Insights - Novo Nordisk has faced challenges, including disappointing fourth-quarter results and negative guidance for fiscal year 2026, leading to a nearly 15% drop in stock price [1][7] - The launch of an oral version of Wegovy is a significant development for Novo Nordisk, as it expands the market rather than cannibalizing existing sales [2][5] Company Performance - Novo Nordisk's stock price has recently declined, with a current price of $47.45 and a market cap of $163 billion [6][7] - The company has a gross margin of 80.90% and a dividend yield of 3.56% [7] Product Development - Oral Wegovy is gaining traction, with increasing prescription volumes and the potential to attract new patients [4][5] - The company is awaiting approval for CagriSema, a next-generation weight loss and diabetes therapy, which could positively impact future sales [8][9] Competitive Landscape - Eli Lilly's success with Oral Wegovy indicates a competitive market, as it prepares to launch its own oral GLP-1 therapy, orforglipron [7][8] - Despite the positive reception of Oral Wegovy, Novo Nordisk anticipates a decline in sales due to competition and government-led drug price negotiations [7][8]